EA202090718A1 - Белки, связывающие nkg2d, cd16 и лектиноподобную молекулу-1 c-типа (cll-1) - Google Patents
Белки, связывающие nkg2d, cd16 и лектиноподобную молекулу-1 c-типа (cll-1)Info
- Publication number
- EA202090718A1 EA202090718A1 EA202090718A EA202090718A EA202090718A1 EA 202090718 A1 EA202090718 A1 EA 202090718A1 EA 202090718 A EA202090718 A EA 202090718A EA 202090718 A EA202090718 A EA 202090718A EA 202090718 A1 EA202090718 A1 EA 202090718A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- antibody
- antigen binding
- binding site
- binds
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762558510P | 2017-09-14 | 2017-09-14 | |
| PCT/US2018/050916 WO2019055677A1 (en) | 2017-09-14 | 2018-09-13 | NKG2D, CD16, AND LIQUID-LIKE MOLECULE-1-LIKE PROTEINS (CLL-1) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202090718A1 true EA202090718A1 (ru) | 2020-07-01 |
Family
ID=65723086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202090718A EA202090718A1 (ru) | 2017-09-14 | 2018-09-13 | Белки, связывающие nkg2d, cd16 и лектиноподобную молекулу-1 c-типа (cll-1) |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20200277384A1 (enExample) |
| EP (1) | EP3681532A4 (enExample) |
| JP (2) | JP2020534269A (enExample) |
| KR (1) | KR20200051789A (enExample) |
| CN (1) | CN111432832A (enExample) |
| AU (1) | AU2018331412A1 (enExample) |
| BR (1) | BR112020005078A2 (enExample) |
| CA (1) | CA3075857A1 (enExample) |
| EA (1) | EA202090718A1 (enExample) |
| IL (1) | IL273206A (enExample) |
| MA (1) | MA50255A (enExample) |
| MX (1) | MX2020002880A (enExample) |
| SG (1) | SG11202002298PA (enExample) |
| WO (1) | WO2019055677A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110944651A (zh) | 2017-02-08 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途 |
| EP4273258A3 (en) | 2017-02-20 | 2024-01-17 | Dragonfly Therapeutics, Inc. | Proteins binding her2, nkg2d and cd16 |
| US12247060B2 (en) | 2018-01-09 | 2025-03-11 | Marengo Therapeutics, Inc. | Calreticulin binding constructs and engineered T cells for the treatment of diseases |
| MX2020008333A (es) | 2018-02-08 | 2020-09-21 | Dragonfly Therapeutics Inc | Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales. |
| CA3090244A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
| CN112119093A (zh) | 2018-02-20 | 2020-12-22 | 蜻蜓治疗公司 | 结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法 |
| EP3765516A2 (en) * | 2018-03-14 | 2021-01-20 | Elstar Therapeutics, Inc. | Multifunctional molecules and uses thereof |
| WO2020010250A2 (en) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| CA3108427A1 (en) | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| CN113164570B (zh) | 2018-08-08 | 2024-05-14 | 蜻蜓疗法股份有限公司 | 结合nkg2d、cd16和肿瘤相关抗原的蛋白质 |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| CN112912400B (zh) | 2018-10-19 | 2025-05-30 | 明尼苏达大学董事会 | Nk接合子分子及其使用方法 |
| AU2020226893B2 (en) | 2019-02-21 | 2025-02-27 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| JP7579795B2 (ja) | 2019-02-21 | 2024-11-08 | マレンゴ・セラピューティクス，インコーポレーテッド | ＮＫｐ３０に結合する抗体分子およびその使用 |
| KR20220004751A (ko) | 2019-05-04 | 2022-01-11 | 인히브릭스, 인크. | CLEC12a 결합 폴리펩타이드 및 이의 용도 |
| AR119393A1 (es) * | 2019-07-15 | 2021-12-15 | Hoffmann La Roche | Anticuerpos que se unen a nkg2d |
| BR112022007128A2 (pt) * | 2019-10-15 | 2022-07-05 | Dragonfly Therapeutics Inc | Ligação de proteínas nkg2d, cd16 e flt3 |
| WO2021138474A2 (en) | 2020-01-03 | 2021-07-08 | Marengo Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| WO2021226163A2 (en) * | 2020-05-06 | 2021-11-11 | Dragonfly Therapeutics, Inc. | Antibodies targeting clec12a and use thereof |
| AU2021268340A1 (en) * | 2020-05-06 | 2022-12-08 | Dragonfly Therapeutics, Inc. | Proteins binding NKG2D, CD16 and CLEC12A |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
| PE20241789A1 (es) | 2021-04-26 | 2024-09-06 | Millennium Pharm Inc | Anticuerpos anti-clec12a y usos de los mismos |
| CN113817065B (zh) * | 2021-09-06 | 2023-04-18 | 深圳市乐土生物医药有限公司 | 一种抗her2的多肽及其用途 |
| CN115850476B (zh) * | 2022-08-09 | 2023-09-05 | 合源康华医药科技(北京)有限公司 | 一种cll1抗体及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040115198A1 (en) * | 2001-02-28 | 2004-06-17 | Fred Hutchinson Cancer Research Center | Activation of lymphocyte populations expressing NKG2D using anti-NKG2D antibodies and ligand derivatives |
| WO2007002905A1 (en) * | 2005-06-29 | 2007-01-04 | University Of Miami | Antibody-immune cell ligand fusion protein for cancer therapy |
| WO2009077483A1 (en) * | 2007-12-14 | 2009-06-25 | Novo Nordisk A/S | Antibodies against human nkg2d and uses thereof |
| EP2014680A1 (en) * | 2007-07-10 | 2009-01-14 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives |
| ES2550384T3 (es) * | 2008-12-18 | 2015-11-06 | Dana-Farber Cancer Institute, Inc. | NKG2D-Fc para la inmunoterapia |
| US9163090B2 (en) * | 2012-05-07 | 2015-10-20 | Cellerant Therapeutics, Inc. | Antibodies specific for CLL-1 |
| BR112015006824A2 (pt) * | 2012-09-27 | 2017-07-04 | Merus B V | anticorpo igg biespecífico, método para produzir um anticorpo igg biespecífico, anticorpo, composição farmacêutica e uso de um anticorpo igg biespecífico |
| EP3851457A1 (en) * | 2016-01-21 | 2021-07-21 | Novartis AG | Multispecific molecules targeting cll-1 |
| MX2019010156A (es) * | 2017-02-27 | 2020-01-09 | Dragonfly Therapeutics Inc | Proteínas multiespecíficas de unión de direccionamiento a anhidrasa carbónica 9 (caix), anoctamina-1 (ano1), mesotelina, antígeno de superficie celular de trofoblasto (trop2), antígeno carcinoembrionario (cea) o claudina-18.2. |
-
2018
- 2018-09-13 MX MX2020002880A patent/MX2020002880A/es unknown
- 2018-09-13 BR BR112020005078-4A patent/BR112020005078A2/pt not_active Application Discontinuation
- 2018-09-13 MA MA050255A patent/MA50255A/fr unknown
- 2018-09-13 US US16/645,613 patent/US20200277384A1/en not_active Abandoned
- 2018-09-13 JP JP2020514936A patent/JP2020534269A/ja active Pending
- 2018-09-13 KR KR1020207010605A patent/KR20200051789A/ko not_active Ceased
- 2018-09-13 EA EA202090718A patent/EA202090718A1/ru unknown
- 2018-09-13 WO PCT/US2018/050916 patent/WO2019055677A1/en not_active Ceased
- 2018-09-13 SG SG11202002298PA patent/SG11202002298PA/en unknown
- 2018-09-13 CN CN201880072887.1A patent/CN111432832A/zh active Pending
- 2018-09-13 EP EP18856132.8A patent/EP3681532A4/en active Pending
- 2018-09-13 AU AU2018331412A patent/AU2018331412A1/en not_active Abandoned
- 2018-09-13 CA CA3075857A patent/CA3075857A1/en active Pending
-
2020
- 2020-03-10 IL IL273206A patent/IL273206A/en unknown
-
2024
- 2024-04-03 JP JP2024060206A patent/JP2024099539A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024099539A (ja) | 2024-07-25 |
| KR20200051789A (ko) | 2020-05-13 |
| EP3681532A4 (en) | 2021-09-01 |
| CA3075857A1 (en) | 2019-03-21 |
| IL273206A (en) | 2020-04-30 |
| EP3681532A1 (en) | 2020-07-22 |
| MX2020002880A (es) | 2020-10-01 |
| AU2018331412A1 (en) | 2020-03-26 |
| JP2020534269A (ja) | 2020-11-26 |
| SG11202002298PA (en) | 2020-04-29 |
| MA50255A (fr) | 2021-05-26 |
| WO2019055677A1 (en) | 2019-03-21 |
| BR112020005078A2 (pt) | 2020-10-13 |
| CN111432832A (zh) | 2020-07-17 |
| US20200277384A1 (en) | 2020-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020002880A (es) | Proteínas que se unen a nkg2d, cd16 y a la molécula 1 similar a lectina de tipo c (cll-1). | |
| EA202091887A1 (ru) | Комбинированная терапия рака с применением мультиспецифических связывающих белков, которые активируют естественные клетки-киллеры | |
| PE20120549A1 (es) | Proteinas biespecificas de union a antigenos | |
| EA202091888A1 (ru) | Вариабельные домены антител, нацеленные на рецептор nkg2d | |
| EA202192090A1 (ru) | Антигенсвязывающие белки против гамма-цепи рецептора il2 | |
| MX2022007636A (es) | Anticuerpos biespecificos caninizados y pares de union biespecificos para el tratamiento contra dermatitis atopica. | |
| WO2018057735A8 (en) | Antibodies for siglec-15 and methods of use thereof | |
| EA201992526A1 (ru) | Стабильные составы анти-ctla4 антител, отдельно и в комбинации с антителами против рецептора 1 программируемой смерти (pd-1), и способы их применения | |
| EA202092417A1 (ru) | Химерные рецепторы к dll3 и способы их применения | |
| EA201691482A1 (ru) | Человеческие антитела к pd-1 | |
| EA202190542A1 (ru) | Сконструированные биспецифические белки | |
| EA202090812A1 (ru) | Новые биспецифические полипептидные комплексы | |
| MX2020012567A (es) | Anticuerpos anti-ox40 y metodos de uso. | |
| EA202191785A1 (ru) | Антитела к ctla4 и способы их применения | |
| EA201990285A1 (ru) | Гетеродимерные иммуноглобулиновые конструкции и способы их получения | |
| EA201491599A1 (ru) | Антитела к матриксной металлопротеиназе 9 | |
| PE20221404A1 (es) | Formulaciones farmaceuticas y regimenes de dosificacion para proteinas de union multiespecificas que se unen a her2, nkg2d y cd16 para el tratamiento del cancer | |
| EA201890296A1 (ru) | Pd-1-связывающие молекулы и способы их применения | |
| EA201690447A1 (ru) | БИСПЕЦИФИЧЕСКИЕ МОНОВАЛЕНТНЫЕ ДИАТЕЛА, КОТОРЫЕ СПОСОБНЫ СВЯЗЫВАТЬСЯ С gpA33 И CD3, И ИХ ПРИМЕНЕНИЯ | |
| EA201891066A1 (ru) | Антитела к ror1 | |
| EA201390146A1 (ru) | Антитела к матриксной металлопротеиназе 9 | |
| MX2024001595A (es) | Anticuerpos btla. | |
| PE20241584A1 (es) | Proteinas que se unen a nkg2d, cd16 y baff-r | |
| EA201491575A1 (ru) | Антитела к матриксной металлопротеиназе 9 | |
| EA202190235A1 (ru) | Антитела к cd33 и способы их применения |